Blueberries Could Help Fight Alzheimer's, UC Research Shows
The blueberry, already labeled a "super fruit for its power to potentially lower the risk of heart disease and cancer, also could be another weapon in the war against Alzheimers disease. In a new study led by researchers at the University of Cincinnati, adults aged 68 and older performed better on cognitive tests after 16 weeks of taking blueberry powder supplements, versus a control group taking a placebo. The research was presented today in a press conference at the American Chemical Society (ACS) meeting in San Diego.
"Our new findings corroborate those of previous animal studies and preliminary human studies, adding further support to the notion that blueberries can have a real benefit in improving memory and cognitive function in some older adults, says Robert Krikorian, PhD, professor in the Department of Psychiatry and Behavioral Neuroscience with the University of Cincinnati College of Medicine. He adds that blueberries beneficial effects could be due to flavonoids called anthocyanins, which have been shown to improve animals cognition.
The study involved 47 adults aged 68 and older with mild cognitive impairment, a risk condition for Alzheimers disease. The researchers gave them either freeze-dried blueberry powder, which is equivalent to a cup of berries, or a placebo powder, once a day for 16 weeks.
"There was improvement in cognitive performance and brain function in those who had the blueberry powder compared with those who took the placebo, Krikorian says. "The blueberry group demonstrated improved memory and improved access to words and concepts. The team also conducted functional magnetic resonance imaging (fMRI), which showed increased brain activity in those who ingested the blueberry powder.
Currently 5.3 million people suffer from Alzheimers disease. But that number is expected to increase, Krikorian notes, as the U.S. population ages. By 2025, the number of Americans with this degenerative disorder could rise 40 percent to more than 7 million, and it could almost triple by 2050, according to the Alzheimers Association.
In an effort to find ways to slow down this alarming trend, Krikorian and colleagues at University of Cincinnati Academic Health Center conducted two human studies to follow up on earlier clinical trials.
The second study included 94 people aged 62 to 80, who were divided into four groups. The participants didnt have objectively measured cognitive issues, but they subjectively felt their memories were declining. The groups received blueberry powder, fish oil, fish oil and powder or placebo.
"The results were not as robust as with the first study, Krikorian explained. "Cognition was somewhat better for those with powder or fish oil separately, but there was little improvement with memory. Also, fMRI results also were not as striking for those receiving blueberry powder. He says that the effect may have been smaller in this case because these participants had less severe issues when they entered the study.
Krikorian said the two studies indicate that blueberries may be more effective in treating patients with cognitive impairments, but may not show measurable benefit for those with minor memory issues or who have not yet developed cognitive problems.
In the future, the team plans to conduct a blueberry study with a younger group of people, aged 50 to 65. The group would include people at risk of developing Alzheimers, such as those who are obese, have high blood pressure or high cholesterol. This work could help the researchers determine if blueberries could help prevent the onset of Alzheimers symptoms.
The researchers presented their work today at the 251st National Meeting & Exposition of the ACS, a nonprofit organization chartered by the U.S. Congress. With more than 158,000 members, ACS is the worlds largest scientific society and a global leader in providing access to chemistry-related research.
Krikorian acknowledges funding from the U.S. Highbush Blueberry Council, the National Institute on Aging and Wild Blueberries of North America.
Related Stories
UC experts present neurology research at national conference
April 17, 2026
University of Cincinnati researchers will present abstracts at the 2026 American Academy of Neurology Annual Meeting April 18 to 22 in Chicago.
AI advances in the liver disease field
April 15, 2026
MASH represents the advanced inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease), where fat accumulation in the liver triggers fibrosis and progressive liver injury. According to a recent MedCentral article, more AI-based clinical assessment tools in MASH are needed.
UC Graduate College honors 2026 Graduate Student Research Award recipients during Research + Innovation Week
April 15, 2026
The University of Cincinnati Graduate College is proud to announce the recipients of the 2026 Graduate Student Research Awards, recognizing doctoral students whose research, scholarship, and creative work demonstrate excellence in innovation, impact and interdisciplinarity.